ORIGINAL RESEARCH article
Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1644828
Increased serum anti-ceramide antibodies and decreased sphingosine-1-phosphate levels in patients with obstructive sleep apnea syndrome as potential markers of endothelial dysfunction
Provisionally accepted
- 1Instytut Immunologii i Terapii Doswiadczalnej im Ludwika Hirszfelda Polskiej Akademii Nauk, Wrocław, Poland
- 2Wroclaw Medical University, Wrocław, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Sphingosine-1-phosphate (S1P) and ceramide are bioactive sphingolipids that have been associated with some obstructive sleep apnea (OSA) comorbidities like coronary artery disease (CAD), insulin resistance, diabetes mellitus, hypertension, cardiac dysfunction, and ischemic stroke. On the other hand, S1P and ceramide play key roles in maintaining endothelial homeostasis, which is impaired by repetitive hypoxia/reoxygenation and sleep fragmentation characteristic of OSA. Since the exact role of S1P and ceramide in OSA is still poorly explored, the present study aimed to compare the levels of S1P and anti-ceramide antibodies (ceramide-Ab) in OSA patients and controls.Methods: We recruited 153 subjects (104 patients and 49 controls). The concentrations of anticeramide antibodies and S1P were measured using the ELISA technique.Results: We detected significantly higher levels of anti-ceramide antibodies in the OSA group than in the control group (median 318.0 vs. 247.7 ng/ml, p < 0.0001). By contrast, S1P levels were markedly higher in the controls than in the OSA patients (median 1006.0 vs. 573.9 ng/ml, p < 0.0001). No correlation was observed between either ceramide-Ab or S1P concentrations and the following variables: OSA severity (AHI), desaturation index (DI), BMI, average SaO2, minimum SaO2, and Creactive protein (CRP). Additionally, we noted a positive correlation between BMI and AHI (Spearman r = 0.5051, p < 0.0001), as well as between BMI and DI (Spearman r = 0.55, p < 0.0001). Conversely, BMI negatively correlated with mean SaO2 (Spearman r = -0.58, p < 0.0001) and with minimum SaO2 (Spearman r = -0.44, p < 0.0001). A middle-strong positive correlation was observed between BMI and serum level of CRP (Spearman r = 0.60, p < 0.0001).We demonstrated that anti-ceramide antibody levels were significantly increased, whereas S1P levels were decreased in patients with obstructive sleep apnea in comparison to healthy subjects. These results suggest that the balance between ceramide and S1P (known as sphingolipid rheostat) may be dysregulated in the course of OSA. We suggest that ceramide-Ab might become a valuable positive biomarker of the disease with S1P as a negative biomarker.
Keywords: obstructive sleep apnea syndrome, sphingosine 1-phosphate, anti-ceramide antibodies, ceramide, Sphingolipid rheostat, endothelial dysfunction
Received: 10 Jun 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Wiśniewski, Wisniewska, Lewandowski, Nowak and Kosacka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Monika Kosacka, Wroclaw Medical University, Wrocław, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.